Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015).-论文-万方医学网

作者： Daisaku,Yamada ^[1] ; Shogo,Kobayashi ^[2] ; Hidenori,Takahashi ^[1] ; Yoshifumi,Iwagami ^[3] ; Hirofumi,Akita ^[1] ; Kei,Asukai ^[3] ; Junzo,Shimizu ^[3] ; Terumasa,Yamada ^[4] ; Masahiro,Tanemura ^[5] ; Shigekazu,Yokoyama ^[6] ; Masanori,Tsujie ^[7] ; Tadafumi,Asaoka ^[8] ; Yutaka,Takeda ^[9] ; Osakuni,Morimoto ^[10] ; Akira,Tomokuni ^[11] ; Yuichiro,Doki ^[12] ; Hidetoshi,Eguchi ^[1]

作者单位： Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan. ^[1] Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan. skobayashi@gesurg.med.osaka-u.ac.jp. ^[2] Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan. ^[3] Department of Gastroenterological Surgery, Toyonaka Municipal Hospital, Toyonaka, Japan. ^[4] Department of Gastroenterological Surgery, Higashiosaka City Medical Center, Higashiosaka, Japan. ^[5] Department of Gastroenterological Surgery, Rinku General Medical Center, Izumisano, Japan. ^[6] Department of Gastroenterological Surgery, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan. ^[7] Department of Gastroenterological Surgery, Osaka Rosai Hospital, Sakai, Japan. ^[8] Department of Gastroenterological Surgery, Osaka Police Hospital, Osaka, Japan. ^[9] Department of Gastroenterological Surgery, Kansai Rosai Hospital, Amagasaki, Japan. ^[10] Department of Surgery, Japan Community Health Care Organization Osaka Hospital, Osaka, Japan. ^[11] Department of Gastroenterological Surgery, Osaka General Medical Center, Osaka, Japan. ^[12]

主题词人类(Humans);脱氧胞苷(Deoxycytidine);女(雌)性(Female);男(雄)性(Male);紫杉酚(Paclitaxel);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);胰腺肿瘤(Pancreatic Neoplasms);喃氟啶(Tegafur);白蛋白类(Albumins);氧嗪酸(Oxonic Acid);癌, 胰腺管(Carcinoma, Pancreatic Ductal);肿瘤辅助疗法(Neoadjuvant Therapy);中年人(Middle Aged);复方合剂(Drug Combinations);老年人(Aged);存活率(Survival Rate);随访研究(Follow-Up Studies);预后(Prognosis);成年人(Adult);腺癌(Adenocarcinoma)

DOI 10.1245/s10434-024-15199-8

PMID 38546797

发布时间 2024-07-10

检索历史清除

Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015).

Annals of surgical oncology

相似文献

Annals of surgical oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015).

Annals of surgical oncology

相似文献

Annals of surgical oncology

相关期刊

检索历史清除